BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11207643)

  • 1. Hydrocortisone replacement dosage influences intraocular pressure in patients with primary and secondary hypocortisolism.
    Li Voon Chong JS; Sen J; Johnson Z; Kyle G; MacFarlane IA
    Clin Endocrinol (Oxf); 2001 Feb; 54(2):267-71. PubMed ID: 11207643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrocortisone replacement therapy in children and adolescents with hypopituitarism.
    DeVile CJ; Stanhope R
    Clin Endocrinol (Oxf); 1997 Jul; 47(1):37-41. PubMed ID: 9302370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metabolic assessment of hydrocortisone replacement therapy in patients with primary adrenocortical insufficiency].
    Fichna M; Gryczyńska M; Sowińska A; Sowiński J
    Przegl Lek; 2011; 68(2):96-102. PubMed ID: 21751518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism.
    Dunne FP; Elliot P; Gammage MD; Stallard T; Ryan T; Sheppard MC; Stewart PM
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):623-9. PubMed ID: 8548948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency.
    Ekman B; Bachrach-Lindström M; Lindström T; Wahlberg J; Blomgren J; Arnqvist HJ
    Clin Endocrinol (Oxf); 2012 Jul; 77(1):18-25. PubMed ID: 22288685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid replacement therapy: are patients over treated and does it matter?
    Peacey SR; Guo CY; Robinson AM; Price A; Giles MA; Eastell R; Weetman AP
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):255-61. PubMed ID: 9156031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulsatile thyrotropin secretion in patients with Addison's disease during variable glucocorticoid therapy.
    Hangaard J; Andersen M; Grodum E; Koldkjaer O; Hagen C
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2502-7. PubMed ID: 8675567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circadian hormone profiles and insulin sensitivity in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy.
    Björnsdottir S; Øksnes M; Isaksson M; Methlie P; Nilsen RM; Hustad S; Kämpe O; Hulting AL; Husebye ES; Løvås K; Nyström T; Bensing S
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):28-35. PubMed ID: 25400085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement.
    Ross IL; Levitt NS; Van der Walt JS; Schatz DA; Johannsson G; Haarburger DH; Pillay TS
    Horm Metab Res; 2013 Jan; 45(1):62-8. PubMed ID: 22893258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional glucocorticoid replacement overtreats adult hypopituitary patients with partial ACTH deficiency.
    Agha A; Liew A; Finucane F; Baker L; O'Kelly P; Tormey W; Thompson CJ
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):688-93. PubMed ID: 15163331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life in patients with Addison's disease: effects of different cortisol replacement modes.
    Riedel M; Wiese A; Schürmeyer TH; Brabant G
    Exp Clin Endocrinol; 1993; 101(2):106-11. PubMed ID: 8405139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diurnal variation of intraocular pressure in normal and ocular hypertensive subjects of China.
    Xi XR; Qureshi IA; Wu XD; Huang YB; Lu H; Shiarkar E
    J Pak Med Assoc; 1996 Aug; 46(8):171-4. PubMed ID: 8936973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison's disease.
    Giordano R; Guaraldi F; Marinazzo E; Fumarola F; Rampino A; Berardelli R; Karamouzis I; Lucchiari M; Manetta T; Mengozzi G; Arvat E; Ghigo E
    Endocrine; 2016 Feb; 51(2):360-8. PubMed ID: 26184416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seasonal and diurnal variations of ocular pressure in ocular hypertensive subjects in Pakistan.
    Qureshi IA; Xiao RX; Yang BH; Zhang J; Xiang DW; Hui JL
    Singapore Med J; 1999 May; 40(5):345-8. PubMed ID: 10489493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia.
    Verma S; Vanryzin C; Sinaii N; Kim MS; Nieman LK; Ravindran S; Calis KA; Arlt W; Ross RJ; Merke DP
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):441-7. PubMed ID: 19486026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring.
    Cho SY; Kim YY; Yoo C; Lee TE
    Jpn J Ophthalmol; 2016 Jan; 60(1):27-34. PubMed ID: 26411460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol.
    Rácz P; Ruzsonyi MR; Nagy ZT; Gaygi Z; Bito LZ
    Arch Ophthalmol; 1996 Mar; 114(3):268-73. PubMed ID: 8600885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia.
    Merza Z; Rostami-Hodjegan A; Memmott A; Doane A; Ibbotson V; Newell-Price J; Tucker GT; Ross RJ
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):45-50. PubMed ID: 16817818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of low-dose oral hydrocortisone replacement versus short-term reproduction of physiological serum cortisol concentrations on insulin action in adult-onset hypopituitarism.
    McConnell EM; Bell PM; Ennis C; Hadden DR; McCance DR; Sheridan B; Atkinson AB
    Clin Endocrinol (Oxf); 2002 Feb; 56(2):195-201. PubMed ID: 11874410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma.
    Konstas AG; Tsironi S; Vakalis AN; Nasr MB; Stewart JA; Nelson LA; Stewart WC
    Acta Ophthalmol; 2009 Feb; 87(1):71-6. PubMed ID: 19178390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.